Kura Oncology Announces First-In-Human Data From The FIT-001 Clinical Trial Of Darlifarnib In Combination With Adagrasib In Heavily Pretreated Patients With KRAS G12C-Mutated Advanced Solid Tumors

– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients –

– ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients –

– Results reinforce darlifarnib's potential as a precision combination agent across targeted therapies –

– Clear clinical activity in KRASi-experienced patients and manageable safety profile –

– Virtual investor event on June 3, 2026, at 12:15 p.m. PT / 3:15 p.m. ET –